

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
SCOPE AND FORMAT.....	2
METHODOLOGY AND INFORMATION SOURCES.....	2
INTENDED AUDIENCE.....	2
ANALYST CREDENTIALS.....	3
RELATED REPORTS.....	3
BCC ON-LINE SERVICES.....	3
DISCLAIMER.....	4
 CHAPTER TWO: SUMMARY.....	 5
SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL MARKET FOR DRUG DISCOVERY</i>	
<i>TECHNOLOGIES AND PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR DRUG DISCOVERY</i>	
<i>TECHNOLOGIES AND PRODUCTS, 2011–2017 (\$ BILLIONS)</i>	7
 CHAPTER THREE: OVERVIEW.....	 8
INTRODUCTION.....	8
INTRODUCTION (CONTINUED).....	9
PRECLINICAL TESTING AND SUBMISSION OF AN	
INVESTIGATIONAL NEW DRUG.....	10
CLINICAL TRIALS.....	11
SUBMISSION OF NEW DRUG APPLICATION OR	
BIOLOGICAL LICENSING APPLICATION.....	12
POST-FOOD AND DRUG ADMINISTRATION APPROVAL.....	13
IMPACT OF GOVERNMENT REGULATIONS AND REGULATORY	
APPROVALS ON THE DRUG DISCOVERY INDUSTRY.....	14
NEW DRUG APPROVALS.....	14
<i>TABLE 1 NEW MOLECULAR ENTITY (NME) APPLICATIONS</i>	
<i>VERSUS APPROVAL BY THE FDA, 2006–2010</i>	14
<i>FIGURE 1 NEW MOLECULAR ENTITY (NME) APPLICATIONS</i>	
<i>VERSUS APPROVAL BY THE FDA, 2006–2010</i>	14
New Drug Approvals (Continued).....	15
TIMELINE AND COSTS.....	16
<i>FIGURE 2 TIMELINE FOR DRUG DEVELOPMENT PROCESS</i>	16
<i>TABLE 2 FACTS ABOUT DRUG DISCOVERY AND DEVELOPMENT</i>	
<i>FOR 2010</i>	17
<i>TABLE 3 R&D SPENDING FOR DRUG DISCOVERY IN</i>	
<i>BIOPHARMACEUTICAL COMPANIES, 2008–2012 (\$ MILLIONS)</i>	17
IMPORTANCE OF TECHNOLOGY IN DRUG DISCOVERY.....	18
MARKET LANDSCAPE IN THE DRUG DISCOVERY SECTOR.....	19
<i>TABLE 4 FDA-APPROVED DRUGS FOR SALE IN THE U.S. 2001-2011</i>	20

<i>TABLE 5 GLOBAL PHARMACEUTICAL MARKET VALUE, THROUGH 2017 (\$ BILLIONS)</i>	21
MARKET PARTICIPANTS IN THE DRUG DISCOVERY SECTOR	21
<i>TABLE 6 TOP GLOBAL PHARMACEUTICAL CORPORATION RANKING, 2009</i>	22
<i>TABLE 7 NUMBER OF DEALS AND THEIR VALUE IN THE PHARMACEUTICAL INDUSTRY IN DIFFERENT COUNTRIES, 2010</i>	23
PATENTS AND DRUG DISCOVERY TECHNOLOGY	23
PATENTS AND DRUG DISCOVERY ... (CONTINUED).....	24
PATENTS AND DRUG DISCOVERY ... (CONTINUED).....	25
<i>TABLE 8 PATENT APPLICATION IN DRUG DISCOVERY FROM MARCH 2012</i>	26
<i>TABLE 8 (CONTINUED)</i>	27
 CHAPTER FOUR: GENOMICS RESEARCH AND DRUG DISCOVERY	
TECHNOLOGIES	28
OVERVIEW	28
GENOMICS STUDIES AS A PLATFORM FOR DRUG DISCOVERY TECHNOLOGIES.....	29
POLYMERASE CHAIN REACTION TECHNOLOGY AS BASIS FOR DRUG DISCOVERY	30
<i>TABLE 9 GLOBAL REAL-TIME POLYMERASE CHAIN REACTION MARKET, THROUGH 2017 (\$ BILLIONS)</i>	31
DNA MICROARRAYS AND DRUG DEVELOPMENT	32
DNA Microarrays and Drug Development (Continued)	33
<i>TABLE 10 GLOBAL MARKET FOR DNA MICROARRAYS, THROUGH 2017 (\$ BILLIONS)</i>	34
RNA RESEARCH AS DRUG DISCOVERY PLATFORM FOR NEW TECHNOLOGIES DEVELOPMENT.....	35
RNA Research as Drug Discovery ... (Continued)	36
RNA Interference as Approach to Drug Discovery	37
<i>TABLE 11 GLOBAL RNA INTERFERENCE MARKET, THROUGH 2017 (\$ MILLIONS)</i>	38
Market Participants in the Drug Discovery Sector.....	38
Market Participants ... (Continued)	39
NEXT-GENERATION SEQUENCING AS A TECHNOLOGY FOR DRUG DISCOVERY RESEARCH.....	40
Next-Generation Sequencing ... (Continued).....	41
<i>TABLE 12 GLOBAL NEXT-GENERATION SEQUENCING MARKET, THROUGH 2017 (\$ MILLIONS)</i>	42
Next-Generation Sequencing Market Participants.....	43
Next-Generation ... (Continued)	44

<i>TABLE 13 NEXT-GENERATION SEQUENCING MARKET SHARES BY COMPANY, 2012 (%)</i>	45
EPIGENETICS APPROACH AS A PLATFORM FOR DRUG DISCOVERY	45
DNA METHYLATION	46
HISTONE METHYLATIONS AND MODIFICATIONS	47
<i>TABLE 14 PERCENTAGE OF COMMERCIAL KITS GENERALLY PURCHASED FOR EPIGENETIC RESEARCH (%)</i>	48
Market Evaluation for Drug Discovery in Epigenetics Research	48
<i>TABLE 15 GLOBAL MARKET FOR RESEARCH AND DRUG DISCOVERY IN EPIGENETICS, THROUGH 2017 (\$ BILLIONS)</i>	49
<i>TABLE 16 SALES OF FOUR EPIGENETIC DRUGS, 2009–2011 (\$ MILLIONS)</i>	50
SUMMARY AND EVALUATION OF GENOMICS-BASED DRUG DISCOVERY TECHNOLOGY MARKET	51
<i>TABLE 17 GLOBAL MARKET FOR GENOMICS-BASED DRUG DISCOVERY PLATFORMS, THROUGH 2017 (\$ BILLIONS)</i>	51
CHAPTER FIVE: PROTEOMICS RESEARCH AS A DRUG DISCOVERY TECHNOLOGY AND PLATFORM	52
OVERVIEW	52
PROTEOMICS TECHNOLOGIES THE IN DRUG DISCOVERY MARKET	53
PROTEIN ISOLATION AND IDENTIFICATION TECHNOLOGY FOR BIOMARKER OR DRUG TARGET DISCOVERY	53
Size Exclusion Chromatography	54
Separation Based on Charge or Hydrophobicity	54
Affinity Chromatography	55
Immunoaffinity Chromatography	55
High-Performance Liquid Chromatography as One of the Main Technologies in Proteomics Drug Discovery	55
High-Performance Liquid (Continued)	56
Sample Injectors	57
Pumps	57
Columns	57
<i>TABLE 18 GLOBAL HIGH-PERFORMANCE (OR HIGH-PRESSURE) LIQUID CHROMATOGRAPHY (HPLC) MARKET, THROUGH 2017 (\$ BILLIONS)</i>	58
<i>TABLE 19 PERCENTAGE OF CUSTOMER DISTRIBUTION IN COLUMN SEPARATION MARKET IN 2011</i>	59
PROTEIN IDENTIFICATION AND CHARACTERIZATION TECHNIQUES IN PROTEOMICS DRUG DISCOVERY	59
Mass Spectrometry and the Drug Discovery Sector	59

Mass Spectrometry Instruments	60
Ionization Procedure	60
Matrix-Assisted Laser Desorption/Ionization (MALDI)	61
Electrospray Ionization (ESI)	61
Atmospheric Pressure Chemical Ionization (APCI)	61
Mass Analyzers	62
Quadrupole	62
Time-of-Flight Mass Spectrometry	62
Quadrupole—Time-of-Flight (Q-TOF)	63
Ion Trap Mass Spectroscopy	63
Orbitrap	64
<i>TABLE 20 EXAMPLES OF MASS SPECTROMETRY ANALYZERS USED IN THE PHARMACEUTICAL INDUSTRY</i>	65
Market Overview for Mass Spectrometry	65
<i>TABLE 21 GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 (\$ BILLIONS)</i>	65
Main Players in Mass Spectrometry Industry	66
NMR (NUCLEAR MAGNETIC RESONANCE) APPROACH IN PROTEOMICS DRUG DISCOVERY	67
<i>TABLE 22 PERCENTAGE OF TOTAL NUCLEAR MAGNETIC RESONANCE (NMR) APPLICATIONS IN VARIOUS SECTORS (%)</i>	68
<i>TABLE 23 GLOBAL NUCLEAR MAGNETIC RESONANCE (NMR) MARKET, THROUGH 2017 (\$ MILLIONS)</i>	68
X-RAY CRYSTALLOGRAPHY	69
X-Ray Crystallography (Continued)	70
TWO-DIMENSIONAL GEL APPROACH AS A TECHNOLOGY IN PROTEOMICS DRUG DISCOVERY	71
<i>TABLE 24 GLOBAL MARKET FOR TWO-DIMENSIONAL (2D) GEL ANALYSIS, THROUGH 2017 (\$ MILLIONS)</i>	71
Two-Dimensional Gel Approach ... (Continued)	72
PROTEIN-PROTEIN INTERACTION IDENTIFICATION TECHNIQUES IN DRUG DISCOVERY	73
PROTEIN MICROARRAYS AS PART OF A DRUG DISCOVERY PLATFORM	74
<i>TABLE 25 GLOBAL PROTEIN CHIP MARKET, THROUGH 2017 (\$ MILLIONS)</i>	75
Protein Microarrays ... (Continued)	76
PROTEOMICS-BASED DRUG DISCOVERY MARKET LANDSCAPE	77
<i>TABLE 26 PROTEOMICS MARKET PARTICIPANTS BY INDUSTRY SEGMENT</i>	77
PROTEOMICS-BASED ... (CONTINUED)	78

<i>TABLE 27 GLOBAL PROTEOMICS DRUG DISCOVERY TECHNOLOGY MARKET, THROUGH 2017 (\$ BILLIONS)</i>	79
PROTEOMICS-BASED ... (CONTINUED)	80
CHAPTER SIX: METABOLOMICS AS DRUG DISCOVERY PLATFORM.....	81
OVERVIEW.....	81
GENERAL TECHNIQUES AND METHODS FOR METABOLITE PROFILING	81
METABOLOMICS APPLICATIONS AND DRUG DISCOVERY	82
Market Evaluation for Metabolomic Application.....	83
<i>TABLE 28 GLOBAL MARKET FOR METABOLOMICS APPLICATIONS, THROUGH 2017 (\$ MILLIONS)</i>	84
NEW TECHNOLOGICAL PLATFORMS	84
FURTHER DEVELOPMENT OF BIOINFORMATICS AND CHEMOMETRICS STUDIES	84
Market Participants in the Metabolomics Industry	85
<i>TABLE 29 SELECT MARKET PARTICIPANTS IN THE METABOLOMICS MARKET</i>	85
Market Participants ... (Continued)	86
Market Participants ... (Continued)	87
CHAPTER SEVEN: HIGH-THROUGHPUT SCREENING IN DRUG DISCOVERY.....	88
OVERVIEW.....	88
HIGH-CONTENT SCREENING AS HIGH-IMPACT SECTOR OF THE HIGH-THROUGHPUT SCREENING INDUSTRY	89
High-content Screening ... (Continued).....	90
<i>TABLE 30 GLOBAL MARKET FOR HIGH-THROUGHPUT SCREENING APPROACH IN DRUG DISCOVERY, THROUGH 2017 (\$ BILLIONS)</i>	91
Positive and Negative Drivers Affecting the High-Throughput Screening Market for Drug Discovery	91
<i>TABLE 31 GEOGRAPHICAL DISTRIBUTION OF HIGH-THROUGHPUT SCREENING MARKET USERS FOR 2012 (%)</i>	92
<i>TABLE 32 EFFECT OF NANODROP TECHNOLOGY ON COSTS IN TYPICAL LUMINESCENCE ASSAYS</i>	93
<i>TABLE 33 MAIN MARKET PROVIDERS IN HIGH-THROUGHPUT SCREENING IN 2012</i>	94
CHAPTER EIGHT: BIOINFORMATICS AS A PLATFORM FOR DRUG DISCOVERY.....	95
OVERVIEW.....	95
OVERVIEW (CONTINUED)	96
<i>TABLE 34 GLOBAL MARKET FOR BIOINFORMATICS PRODUCTS THROUGH 2017 (\$ BILLIONS)</i>	97

HARDWARE, INSTRUMENTS AND SOFTWARE	
DEVELOPMENT	97
DATABASE AND CONTENT PRODUCTS AND SERVICES	97
DATA MANAGEMENT AND STORAGE	98
MARKET LANDSCAPE IN BIOINFORMATICS INDUSTRY FOR	
DRUG DISCOVERY	98
<i>TABLE 35 FREE MAJOR ONLINE SOURCES OF GENOMIC AND</i>	
<i>PROTEOMIC INFORMATION</i>	<i>99</i>
<i>TABLE 36 EXAMPLE OF ANNUAL REVENUES OF SOME MARKET</i>	
<i>PARTICIPANTS IN THE BIOINFORMATICS MARKET FOR DRUG</i>	
<i>DISCOVERY, 2009-2011 (\$ MILLIONS)</i>	<i>100</i>
MARKET LANDSCAPE IN ... (CONTINUED)	101
CHAPTER NINE: CELLULAR ASSAYS AS TECHNOLOGY AND	
PLATFORM FOR DRUG DISCOVERY	102
OVERVIEW	102
<i>TABLE 37 GLOBAL SHARES OF CELL-BASED ASSAYS MARKET BY</i>	
<i>CATEGORY, 2012 (%)</i>	<i>102</i>
G-PROTEIN COUPLED RECEPTORS (GPCR) AS A TARGET	
FOR CELL-BASED ASSAY DEVELOPMENT IN THE	
DRUG DISCOVERY INDUSTRY	103
ION CHANNELS AS TARGETS FOR CELL-BASED ASSAY	
DEVELOPMENT	104
Cell-Based Kinase Assays	104
Cell-Based ... (Continued)	105
<i>TABLE 38 GLOBAL MARKET SHARES OF CELL BIOLOGY</i>	
<i>REAGENTS BY PRODUCT CATEGORY (%)</i>	<i>106</i>
<i>TABLE 39 GLOBAL MARKET FOR CELL BIOLOGY REAGENTS,</i>	
<i>THROUGH 2017 (\$ BILLIONS)</i>	<i>106</i>
Light Microscopy	107
Fluorescent Microscopy	107
Confocal Microscopy	107
Electron Microscopy	108
<i>TABLE 40 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR DRUG</i>	
<i>DISCOVERY, THROUGH 2017 (\$ BILLIONS)</i>	<i>108</i>
MARKET PARTICIPANTS IN THE CELL-BASED DRUG	
DISCOVERY MARKET	109
MARKET PARTICIPANTS IN THE ... (CONTINUED)	110
<i>TABLE 41 EXAMPLES OF STEM CELL RESEARCH ASPECTS THAT</i>	
<i>REQUIRE DEVELOPMENT OF SPECIFIC RESEARCH TOOLS,</i>	
<i>ASSAYS AND SERVICES</i>	<i>111</i>
<i>TABLE 42 SELECT REAGENTS PROVIDERS FOR STEM CELL</i>	
<i>RESEARCH AND DRUG DISCOVERY</i>	<i>112</i>
<i>TABLE 42 (CONTINUED)</i>	<i>113</i>

<i>TABLE 43 EXAMPLES OF STEM CELL POLICIES IN DIFFERENT COUNTIES</i>	114
<i>TABLE 43 (CONTINUED)</i>	115
CHAPTER TEN: COMBINATORIAL AND MEDICINAL CHEMISTRY AS A TECHNOLOGY AND PLATFORM FOR DRUG DISCOVERY	116
OVERVIEW	116
OVERVIEW (CONTINUED)	117
COMBINATORIAL CHEMISTRY TECHNOLOGY.....	118
COMBINATORIAL CHEMISTRY ...(CONTINUED)	119
NATURE AS A SOURCE OF DRUGS	120
MARKET ESTIMATES FOR COMBINATORIAL CHEMISTRY	120
<i>TABLE 44 GLOBAL MARKET FOR COMBINATORIAL CHEMISTRY IN DRUG DISCOVERY, THROUGH 2017 (\$ BILLIONS)</i>	121
CHAPTER ELEVEN: BIOANALYTICAL INSTRUMENTS IN THE DRUG DISCOVERY SECTOR.....	122
OVERVIEW	122
<i>TABLE 45 GLOBAL MARKET FOR BIOANALYTICAL INSTRUMENTS IN DRUG DISCOVERY, THROUGH 2017 (\$ BILLIONS)</i>	123
CHAPTER TWELVE: NOVEL AND INNOVATIVE TRENDS IN DRUG DISCOVERY TECHNOLOGY DEVELOPMENT.....	124
SYNTHETIC BIOLOGY IN DRUG DISCOVERY.....	124
SYSTEMS BIOLOGY AS DRUG DISCOVERY PLATFORM.....	125
<i>TABLE 46 ESTIMATED VALUE OF SYSTEMS BIOLOGY MARKET, THROUGH 2017 (\$ MILLIONS)</i>	126
SYSTEMS BIOLOGY AS DRUG ... (CONTINUED).....	127
NANOTECHNOLOGY AS A NEW ESSENTIAL TREND IN DRUG DISCOVERY AND DEVELOPMENT	128
<i>TABLE 47 MEDICAL PRODUCT EXAMPLES WITH FUNCTIONAL NANOTECH COMPONENTS</i>	129
<i>TABLE 47 (CONTINUED)</i>	130
<i>TABLE 48 GLOBAL MARKET FOR NANOMEDICINE PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	130
NANOTECHNOLOGY AS A NEW ... (CONTINUED)	131
CHAPTER THIRTEEN: MARKET SUMMARY	132
MARKET SUMMARY.....	132
MARKET SUMMARY (CONTINUED)	133
<i>TABLE 49 GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	134
<i>FIGURE 3 GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, 2011–2017 (\$ BILLIONS)</i>	134
MARKET SUMMARY (CONTINUED)	135

CHAPTER FOURTEEN: COMPANY PROFILES	136
ACCELRY'S INC.	136
AGILENT TECHNOLOGIES	137
ILLUMINA INC.	138
ISIS PHARMACEUTICALS	139
LUMINEX CORP.	140
WATERS CORP.	141
WATERS CORP.(CONTINUED).....	142

APPENDIX: LIST OF SELECT COMPANIES REPRESENTING THE

DRUG DISCOVERY INDUSTRY	143
ACTIVE MOTIF	143
ADVANCED CELL TECHNOLOGY INC.....	143
AFFYMETRIX.....	143
ALDAGEN INC.....	143
ALNYLAM PHARMACEUTICALS	143
ASTRAZENECA PHARMACEUTICAL LP	144
AVIVA BIOSCIENCES CORP.	144
AURORA BIOMED INC.....	144
BD BIOSCIENCES	144
BECKMAN COULTER INC.....	144
BIO-RAD LABORATORIES	144
BIOMYX TECHNOLOGY.....	145
BIOVISION	145
BRUKER CORP.	145
BTX INSTRUMENT DIVISION.....	145
CALIPER LIFE SCIENCES	145
CAPRICOR INC.....	145
CELL BIOSCIENCES INC.....	146
CELLCENTRIC LTD.....	146
CELGENE CORP.....	146
CEPHEID	146
CERES NANOSCIENCES	146
CHEMBRIDGE CORP.....	146
CHEMDIV	147
CHENOMX.....	147
CLONTECH LABORATORIES.....	147
COMPLETE GENOMICS INC.....	147
COMPUGEN LTD.....	147
DEVELOGEN AG	147
DIGILAB INC.	148
ECHELON BIOSCIENCES INC.....	148
EMD4BIOSCIENCES.....	148
EMERALD BIOSYSTEMS	148
EPIGENTEK GROUP INC.....	148

EXIQON A/S.....	148
EVOTEC INC.....	149
FLUIDIGM.....	149
GAMIDA CELL LTD.....	149
GE HEALTHCARE U.K. LTD.....	149
GENECRAFT.....	149
GENOMATICA.....	149
GILSON INC.....	150
HIGH THROUGHPUT GENOMICS INC.....	150
F. HOFFMAN-LA ROCHE AG.....	150
KINEXUS BIOINFORMATICS CORP.....	150
LI-COR.....	150
LIGON DISCOVERY.....	150
LIFE TECHNOLOGIES CORP.....	151
MARINA BIOTECH.....	151
MAXCYTE INC.....	151
METABOLON INC.....	151
MILLIPORE (EMD GROUP).....	151
MOLECULAR DEVICES INC.....	151
NEURALSTEM.....	152
NEW ENGLAND BIOLABS.....	152
NEXTGEN SCIENCES INC.....	152
OSIRIS THERAPEUTICS INC.....	152
PERKIN-ELMER.....	152
PLURISTEM THERAPEUTICS INC.....	152
PROMEGA CORP.....	153
PROTAGEN AG.....	153
PROTEA BIOSCIENCES INC.....	153
PROTEIN DISCOVERY INC.....	153
PROTEOME SYSTEMS.....	153
QIAGEN.....	153
R&D SYSTEMS INC.....	154
SHIMADZU CORP.....	154
SIGMA-ALDRICH.....	154
STEMGENT.....	154
TECAN GROUP LTD.....	154
THERMO FISHER SCIENTIFIC INC.....	154
VIACYTE.....	155